Evidence map›Paper›PMID 42220536›Full record

ArticleFrontiers in immunology2026

Burden of novel and ultra-rare missense variants in the NF-κB pathway genes associated to Ménière's disease.

Pablo Cruz-Granados, Victoria Rivero de Jesus, Andres Soto-Varela, Rocio Gonzalez-Aguado, Jose A Lopez-Escamez

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pablo Cruz-GranadosMeniere Disease Neuroscience Research Program, Faculty of Medicine & Health, School of Medical Sciences, The Kolling Institute, University of Sydney, Sydney, NSW, Australia.
Victoria Rivero de JesusDivision de Otoneurologia, Department of Otorhinolaryngology, Consorci Sanitari Integral Moises Broggi Hospital, University of Barcelona, Barcelona, Spain.
Andres Soto-VarelaDivision of Neurotology, Department of Otorhinolaryngology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
Rocio Gonzalez-AguadoENT Department. Marqués de Valdecilla University Hospital, Santander, Cantabria, Spain.
Jose A Lopez-EscamezMeniere Disease Neuroscience Research Program, Faculty of Medicine & Health, School of Medical Sciences, The Kolling Institute, University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ménière's disease (MD) is an inner ear disorder characterised by tinnitus, sensorineural hearing loss and dizziness, although around 60% of patients also exhibit and immune dysregulation. Transcriptomic studies have identified three distinct immune phenotypes in MD, classified based on systemic inflammation, cytokine profiles and association to autoinflammatory/autoimmune comorbidities. Furthermore, genetic studies have shown aggregation of rare variants in MD patients; however, the relationship between genetic factors and immune responses remains poorly understood. Methods: In this study, we analysed exome data pertaining to NF-κB pathway genes to identify ultrarare variants that could contribute to the immune phenotypes observed in MD. Furthermore, we retrieved MD epigenetic and transcriptomic data to search for the associated molecular signature. We performed protein modelling and receptor-ligand docking, as well as differential transcript usage (DTU) and splicing prediction. Results: We identified ultrarare heterozygous variants in Conclusion: These findings suggest that MD distinct immune phenotypes based on systemic inflammation and may be linked to comorbid autoimmune/autoinflammatory disorders, with rare variants in

Indexed as

Meniere DiseaseMutation, MissenseNF-kappa BSignal TransductionGenetic Predisposition to DiseaseHumansMolecular Docking SimulationReceptors, Tumor Necrosis Factor, Type IIToll-Like Receptor 9Transmembrane Activator and CAML Interactor ProteinNF-kappa BReceptors, Tumor Necrosis Factor, Type IITNFRSF13B protein, humanToll-Like Receptor 9Transmembrane Activator and CAML Interactor ProteinautoimmuneMeniere diseaseNF-κBrare variant analysisRNAseq

Identifiers

PMID42220536
PMCPMC13218865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.